A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
about
Recent advancements of bortezomib in acute lymphocytic leukemia treatmentThe proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathwayBortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young miceIn vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine gliomaTargeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3BPhase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophiesCombination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemiaCombining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanomaA Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupIncreasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in miceNovel agents for the treatment of childhood acute leukemia.GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.Improving access to novel agents for childhood leukemia.Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade.Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United StatesBortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and BimMolecular profiling of childhood cancer: Biomarkers and novel therapiesA phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)Advances in paediatric cancer treatmentRedox control of leukemia: from molecular mechanisms to therapeutic opportunities.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.Neurotoxicity of biologically targeted agents in pediatric cancer trialsA phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemiaTargeted drug discovery for pediatric leukemia.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyPediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Novel targeted drug therapies for the treatment of childhood acute leukemiaMolecular therapeutic approaches for pediatric acute myeloid leukemia.Proteasome inhibitors in acute leukemia.Novel therapies for children with acute myeloid leukaemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Novel targeted therapies in acute lymphoblastic leukemia.Novel approaches to pediatric leukemia treatment.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
P2860
Q26829613-0DF44A82-97E8-41D0-A213-1654C515DBFBQ28477838-49CCE7EA-DDD4-4CCB-8DDD-CCCF206389E3Q28485441-200E5884-E5D0-40E9-BCD0-DB699B98EF27Q28487205-779ACE15-6FF1-4F59-A3D9-F8D8F5146B0FQ28534151-DB1438D0-387B-49A3-AB47-360116FD106DQ30248842-F9F15C3C-611D-4956-8B6A-5A1433864743Q30252776-9770531B-19AD-4378-83F5-FBA66836219FQ33303627-A7090D69-EEC5-4222-8C28-A32698C65868Q33388541-CE014D9E-9F2C-4630-8D6C-E4216B535318Q33711119-41A45C1F-39ED-4151-9A96-A9258AAE4E6AQ33745227-CD233F47-5BE3-4760-9ADD-49A3EFE50755Q33828073-3051BE1A-F5DE-4DA3-81EA-93B3A37407DAQ34051168-35E4B342-F92D-43D3-8B58-A968FD64440FQ34585047-AD9EEF9C-ACB7-4FD9-B014-7A681030C49BQ35175035-ACA20612-9ED9-4B51-AE2C-5575F5B5A614Q35192790-0170033E-773D-4864-B6F1-D216AEEB9ED1Q35208033-51B6007D-F4EA-4DCF-8292-D63EFABD2EF0Q35688742-6B275733-516F-4AD9-AA1E-B3FCB1926487Q35889130-A1C1A9B6-97BF-4C59-909B-8B0006F475C2Q35957567-F6E256DE-0989-4777-B2AF-EA93808E82F4Q35982670-C4A6BF1D-B173-4F30-AB82-5B451DC3E0BCQ36250783-18F4AECA-394C-4740-A6B2-E2C3575908D9Q36438027-FD99663A-25B3-47FA-AA28-AE97F3931C73Q36508630-9E3819CB-BFCB-4DC7-A839-9B67C4D0DABEQ36646486-838F5216-79E9-4F47-A3E1-F6DB101A0F48Q36738818-2D43CCD6-89B2-487C-863A-D150AEB145CDQ36766221-586614CD-6768-4DFD-AD2F-AEF578277866Q36955757-2BDDB7F9-910E-48EA-9525-943E5A9BCED7Q36989223-8A7BF152-59E0-4F62-80A5-D713EC1B100EQ37233146-827B9C45-BC1F-47B7-9C22-66F8038DC4E2Q37301320-1FAD278D-E314-41F5-B107-A77750048F31Q37377911-60AC0501-5901-455F-BD6A-5144A9CDFCE3Q37477482-AFB23976-1E04-4733-9BDD-AA67251DDC14Q37643136-3CE6AB5A-60F1-4F41-BDBC-64BF68F7E395Q38088003-A5D1A807-3A0C-44AB-BAE4-01E5B503D131Q38096798-50FD8185-7302-4672-8C91-9197A86C438AQ38097334-F6E91701-785F-4C8C-80E0-AE6BAC0540B9Q38120551-AA819F59-C360-4A36-91BD-49EBC19B02D2Q38500371-6327058D-7C92-4AFE-BC01-D0FC839A580AQ38813978-877EE881-C8BD-42AB-8CC9-9CCA8F64DA65
P2860
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@en
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@nl
type
label
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@en
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@nl
prefLabel
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@en
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@nl
P2093
P1476
A phase 1 study of the proteas ...... ildren's Oncology Group study.
@en
P2093
Adam H Brockman
Ashish M Ingle
Debananda Pati
John Wright
Lisa R Bomgaars
Martin Paton
Patrick A Thompson
Peter C Adamson
Sharon E Plon
Terzah M Horton
P304
P356
10.1158/1078-0432.CCR-06-2173
P407
P577
2007-03-01T00:00:00Z